• ثبت نام
    • ورود به سامانه
    مشاهده مورد 
    •   صفحهٔ اصلی
    • نشریات انگلیسی
    • Iranian Journal of Pharmaceutical Research
    • Volume 16, Issue 3
    • مشاهده مورد
    •   صفحهٔ اصلی
    • نشریات انگلیسی
    • Iranian Journal of Pharmaceutical Research
    • Volume 16, Issue 3
    • مشاهده مورد
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Association of Warfarin Therapy with <i>APOE</i> and <i>VKORC1</i> Genes Polymorphism in Iranian Population

    (ندگان)پدیدآور
    Rafiee, SajadRajabibazl, MasoumehMeshkani, RezaDaraei, AzamZargari, MehryarSharafeddin, FahimehFazeli, ZahraToffani Milani, AttabakTaherkhani, Maryam
    Thumbnail
    دریافت مدرک مشاهده
    FullText
    اندازه فایل: 
    301.5کیلوبایت
    نوع فايل (MIME): 
    PDF
    نوع مدرک
    Text
    Research article
    زبان مدرک
    English
    نمایش کامل رکورد
    چکیده
    Warfarin is a vitamin K antagonist that genetic and non-genetic factors affected on its doserequirement in the patients with cardio vascular disease. The aim of this study was whetherthe APOE and VKORC1 polymorphisms influence on warfarin dose requirements in the partof Iranian patients. Blood samples were collected from 86 warfarin-treated patients. Afterextraction of genomic DNA, the VKORC1 (rs9923231) and the APOE (rs429358 and rs7412)polymorphisms were genotyped by PCR-RFLP technique. We found that the Iranian patientscarrying genotypes GA or AA of VKORC1 polymorphism tended to receive lower dose ofwarfarin (p = 0.018). Furthermore, the E3/E3 genotype was observed with the frequency morethan 60% in the patients with low dose of warfarin. The BMI and weight also showed a positivecorrelation with warfarin dose. However, it was not statistically significant (p > 0.05). Theresults of this study may be useful in defining of warfarin dose algorithms for Iranian patients.
    کلید واژگان
    Warfarin therapy
    APOE polymorphisms
    VKORC1
    Iranian population
    Cardio vascular disease
    Pharmacotherapy (Clinical Pharmacy)

    شماره نشریه
    3
    تاریخ نشر
    2017-07-01
    1396-04-10
    ناشر
    School of Pharmacy, Shahid Beheshti University of Medical Sciences
    سازمان پدید آورنده
    Department of Clinical Biochemistry, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
    Department of Clinical Biochemistry, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. |School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
    Department of Clinical Biochemistry, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran
    Department of Clinical Biochemistry, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
    Department of Clinical Biochemistry, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
    Department of Clinical Biochemistry, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
    Department of Medical Genetics, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
    Department of Clinical Biochemistry, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
    Cardiovascular Research Center, Modarres Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

    شاپا
    1735-0328
    1726-6890
    URI
    https://dx.doi.org/10.22037/ijpr.2017.2095
    http://ijpr.sbmu.ac.ir/article_2095.html
    https://iranjournals.nlai.ir/handle/123456789/313332

    مرور

    همه جای سامانهپایگاه‌ها و مجموعه‌ها بر اساس تاریخ انتشارپدیدآورانعناوینموضوع‌‌هااین مجموعه بر اساس تاریخ انتشارپدیدآورانعناوینموضوع‌‌ها

    حساب من

    ورود به سامانهثبت نام

    آمار

    مشاهده آمار استفاده

    تازه ترین ها

    تازه ترین مدارک
    © کليه حقوق اين سامانه برای سازمان اسناد و کتابخانه ملی ایران محفوظ است
    تماس با ما | ارسال بازخورد
    قدرت یافته توسطسیناوب